ImmunoCellular Therapeutics Ltd (OTC:IMUC) was downgraded by investment analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

ImmunoCellular Therapeutics (OTC:IMUC) opened at 0.0825 on Friday. The stock’s market capitalization is $10.56 million. ImmunoCellular Therapeutics has a 1-year low of $0.08 and a 1-year high of $0.53. The company’s 50 day moving average is $0.10 and its 200-day moving average is $0.17.

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Stock Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related stocks with our FREE daily email newsletter.